← Leaderboards
R Kiplin Guy
University Of California San Francisco
$13,409,185
Attributed
$21,937,412
Total exposure
15
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,937,412 · 15
By mechanism
R01$13,643,360 · 4
U01$5,396,579 · 1
R33$1,360,442 · 1
P01$702,319 · 1
R21$432,337 · 1
P41$302,375 · 6
Top collaborators
- Spencer A Knapp5 shared
- Dennis E Kyle5 shared
- Scott M Landfear5 shared
- Roman Manetsch5 shared
- Brenda A Schulman5 shared
- Bhuvanesh Singh5 shared
- Jeremy Nicholas Burrows2 shared
- Joseph Derisi2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- David P Toczyski$19,111,630
- Stanley B Prusiner$54,781,835
- Thomas L James$6,218,651
- Katherine Kurshan Matthay$7,757,759
- Fred E Cohen$5,735,573
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsExcretory FunctionMetabolismScaffoldIn VivoIn VitroResearch DesignPharmacologyPharmaceutical ChemistryToxic EffectResistanceStructure-Activity RelationshipDrug ResistanceStructureBaseResponseInhibitor/AntagonistHigh Throughput ScreeningPre-ClinicalLeadPropertyMediatingProgramsSignal Transduction
Grant awards (41)
Interactions between drug combinations and resistance acquisition risk for antimalarial ATP4 inhibitors$755,713
R01 · FY2025 · AI · contact PI
Interactions between drug combinations and resistance acquisition risk for antimalarial ATP4 inhibitors$777,072
R01 · FY2024 · AI · contact PI
Chemical Biology of the Control of Neddylation by DCN1$623,225
R01 · FY2023 · CA · contact PI
Chemical Biology of the Control of Neddylation by DCN1$623,225
R01 · FY2022 · CA · contact PI
Chemical Biology of the Control of Neddylation by DCN1$635,945
R01 · FY2021 · CA · contact PI
Development of Novel Therapeutics for Leishmaniasis$446,184
R33 · FY2021 · AI
Chemical Biology of the Control of Neddylation by DCN1$635,943
R01 · FY2020 · CA · contact PI
Development of Novel Therapeutics for Leishmaniasis$454,661
R33 · FY2020 · AI
Chemical Biology of the Control of Neddylation by DCN1$662,443
R01 · FY2019 · CA · contact PI
Development of Novel Therapeutics for Leishmaniasis$459,597
R33 · FY2019 · AI
Development of Novel Therapeutics for Leishmaniasis$189,589
R21 · FY2018 · AI
Development of Novel Therapeutics for Leishmaniasis$242,748
R21 · FY2017 · AI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2015 · AI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2014 · AI
Validation of New Antimalarial Leads$1,119,476
R01 · FY2013 · AI
Validation of New Antimalarial Leads$1,190,932
R01 · FY2012 · AI
Validation of New Antimalarial Leads$1,238,884
R01 · FY2011 · AI
Development of Antimalarial Preclinical Candidates$1,089,481
U01 · FY2011 · AI · contact PI
Novel Inhibitors of Nuclear Receptor Function$362,571
R01 · FY2011 · DK · contact PI
Development of Antimalarial Preclinical Candidates$1,099,224
U01 · FY2010 · AI · contact PI
Novel Inhibitors of Nuclear Receptor Function$370,228
R01 · FY2010 · DK · contact PI
Development of Antimalarial Preclinical Candidates$1,076,671
U01 · FY2009 · AI · contact PI
Novel Inhibitors of Nuclear Receptor Function$367,111
R01 · FY2009 · DK · contact PI
Development of Antimalarial Preclinical Candidates$1,044,090
U01 · FY2008 · AI · contact PI
Novel Inhibitors of Nuclear Receptor Function$358,182
R01 · FY2008 · DK · contact PI
Development of Antimalarial Preclinical Candidates$1,087,113
U01 · FY2007 · AI · contact PI
Novel Inhibitors of Nuclear Receptor Function$370,251
R01 · FY2007 · DK · contact PI
COMBINATORIAL SYNTHESIS OF QUINACRINE ANALOGS$358,374
P01 · FY2007 · AG · contact PI
THE INHIBITION OF GRIP1/HTR INTERACTIONS$8,926
P41 · FY2007 · RR · contact PI
COMBINATORIAL SYNTHESIS OF QUINACRINE ANALOGS$343,945
P01 · FY2006 · AG · contact PI
THE INHIBITION OF GRIP1/HTR INTERACTIONS$7,655
P41 · FY2006 · RR · contact PI
EFFECTS OF BENZIMIDAZOLE FUNGICIDES ON GENE TRANSCRIPTION IN YEAST$24
P41 · FY2006 · RR · contact PI
THE INHIBITION OF GRIP1/HTR INTERACTIONS$6,432
P41 · FY2005 · RR
Novel Inhibitors of Nuclear Receptor Function$294,337
R01 · FY2004 · DK
THE INHIBITION OF GRIP1/HTR INTERACTIONS$5,972
P41 · FY2004 · RR
Novel Inhibitors of Nuclear Receptor Function$294,337
R01 · FY2003 · DK
Novel Inhibitors of Nuclear Receptor Function$294,337
R01 · FY2002 · DK
Novel Inhibitors of Nuclear Receptor Function$287,284
R01 · FY2001 · DK
INHIBITION OF GRIP1 &HTR INTERACTIONS$273,230
P41 · FY2001 · RR
NOVEL INHIBITORS OF NUCLEAR RECEPTOR FUNCTION$100,000
R55 · FY2000 · DK
INHIBITION OF GRIP1 &HTR INTERACTIONS$136
P41 · FY2000 · RR